Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of OTS-412 in Treatment-refractory Solid Tumors
NCT07170592Phase 1Not yet recruiting
- Sponsor
- Bionoxx
- Start
- Jan 2027
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
01
Overview
Phase 1, open-label trial of OTS-412 in solid tumor (6 cohorts), sponsored by Bionoxx. Primary endpoint: Incidence and severity of adverse events at 180 days. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
OTS-412
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07170592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07170592.